Alzamend Neuro, Inc. (Nasdaq: ALZN), a clinical-stage biopharmaceutical company, is set to present non-clinical data on AL001 at the Society of Toxicology (SOT) Annual Meeting and ToxExpo in Orlando, Florida, from March 16-20, 2025. The presentation will focus on the pharmacokinetics of AL001, a lithium salicylate/L-proline co-crystal, as a potentially beneficial lithium sparing treatment for Bipolar Disorder Type 1, Alzheimer’s Disease, Major Depressive Disorder, and Post-Traumatic Stress Disorder.
Key Findings from the Non-Clinical Study:
- No Undue Adverse Effects: Both AL001 and lithium carbonate treatments did not negatively impact the mice's body weight or clinical signs during the treatment period.
- Reduced Systemic Exposure: AL001 demonstrated lower plasma lithium levels than lithium carbonate, suggesting a reduced risk of adverse systemic effects and an expansion of lithium’s therapeutic index for safety.
- Enhanced Brain Penetration: AL001 showed consistently higher lithium concentrations in brain tissues, particularly at lower doses, compared to lithium carbonate.
- Targeted Brain Structures: The study revealed that different brain regions absorb and retain lithium differently, indicating the potential for treatments to be tailored to target specific brain areas for more precise treatment of brain-related conditions in human studies.
The study involved administering AL001 to 5XFAD mice, a model for Alzheimer’s research, to compare its effects against lithium carbonate. The results suggest that AL001 could offer clinical advantages for conditions like Alzheimer’s, BD, MDD, and PTSD at low doses, potentially reducing the risk of side effects such as thyroid and kidney complications associated with current lithium therapies. This positions AL001 as a promising candidate for safer long-term treatment options, particularly for fragile populations like elderly and Alzheimer’s patients.
Alzamend Neuro is focused on developing novel products for the treatment of Alzheimer’s, BD, MDD, and PTSD, with a mission to rapidly develop and market safe and effective treatments. The company's pipeline includes AL001 and ALZN002, both licensed from the University of South Florida Research Foundation, Inc.
